logo
Plus   Neg
Share
Email

Hikma Pharma Issues Trading Update; Announces FDA Approval Of KLOXXADO

Hikma Pharmaceuticals PLC (HIK,HIK.L) said 2021 is off to a good start with performance in line with the Group's expectations. The Group said its full-year outlook is unchanged and it remains confident in ability to deliver consistent long-term, sustainable growth.

Separately, Hikma Pharmaceuticals announced the approval of KLOXXADO nasal spray 8mg, by the FDA for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Hikma expects KLOXXADO to be available in the second half of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Uber Technologies Inc. (UBER) Wednesday reported a first-quarter loss that narrowed from last year, despite revenues dropping 16%, reflecting a gain from sale of self-driving unit. The ride-hail service's fourth-quarter loss was narrower than Wall Street estimates, but revenues fell short of expectations.... Social media giant Facebook's Workplace business tool has breached the seven million paid subscribers mark at a time when jobs have gone remote and is now the new normal amid the ongoing pandemic. The number of paid subscribers has grown 40 percent from last year. General Motors Co. (GM) Wednesday reported a profit for the first-quarter that surged from last year, driven by strong price and mix performance in North America, strong credit and residual value performance at GM Financial, as well as the industry recovery in China. Earnings per share topped analysts' expectations, while quarterly revenues missed their estimates.
Follow RTT